This invention concerns the use of the compounds of formula
##STR1##
- the N-oxides, the pharmaceutically acceptable addition salts and the
stereochemically isomeric forms thereof, wherein A is CH, CR4 or N;
n is 0 to 4; Q is hydrogen or NR1R2; R1 and
R2 are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy,
C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono-
or di(C1-12alkyl)-amino, mono- or di(C1-12alkyl)aminocarbonyl
wherein each C1-12alkyl may optionally be substituted; or R1 and
R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido
or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is
hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl,
C16alkyloxy-carbonyl,; and R4 is hydroxy, halo, optionally
substituted C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl,
nitro, amino, trihalomethyl, trihalomethyloxy; R5 is hydrogen or C1-4alkyl;
L is optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl,
C3-7cycloalkyl; or L is X1R6 or
X2-Alk-R7 wherein R6 and R7 are
optionally substituted phenyl; X1 and X2 are NR3,
NHNH, NN, O, S,
S(O) or S(O)2; Alk is
C1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally
substituted aliphatic or aromatic heterocyclic radical; for the manufacture of
a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency
Virus) infection. It further relates to new compounds being a subgroup of the compounds
of formula (I), their preparation and compositions comprising them.
|
|
|
